Results 31 to 40 of about 7,789 (204)

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Drugs in Context, 2020
Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which ...
Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, Branimir Anić, Matija Tomšič, Vadim Mazurov, Marija Maksimovic, Orsolya Nagy, Jerzy Świerkot, Tzvetanka Petranova, Tiina Veldi, Asta Baranauskaitė, Catalin Codreanu, Daina Andersone, Roy Fleischmann   +14 more
doaj   +1 more source

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib

Frontiers in Pharmacology, 2023
Objective: To mine the adverse drug event (ADE) signals of upadacitinib based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to provide a reference for the safe clinical use of the drug.Methods: The ADE data for
Yan Wu, Meihao Wei, Jing Zhang
doaj   +1 more source

Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome

JPGN Reports, EarlyView.
Abstract We present a novel case of gastrointestinal strictures in a young girl with Satoyoshi syndrome (SS), highlighting multi‐system features of alopecia universalis, painful muscle cramps with dystonia, aberrant growth velocity, and skeletal abnormalities.
Katherine (Tusia) Pohoreski, Gary Galante, Kiera Pajunen, Marie‐Anne Brundler, Samarjeet Bhandal, Iwona Wrobel   +5 more
wiley   +1 more source

Uncovering the Therapeutic Target and Molecular Mechanism of Upadacitinib on Sjogren’s Syndrome

Biomedical Engineering and Computational Biology
Objective: Upadacitinib, a selective Janus associated kinase 1 (JAK-1) inhibitor, can be prescribed particularly for the clinical treatment with Crohn’s disease or rheumatoid arthritis.
Youguo Yang, Yuan Liu, Xiaofen Li, Yongping Zeng, Weiqian He, Juan Zhou   +5 more
doaj   +1 more source

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

RMD Open
Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton’s tyrosine kinase inhibitor ...
Joan T Merrill, Yoshiya Tanaka, Amit Saxena, Xiaofeng Zeng, Martin Aringer, David D’Cruz, Kristin M D’Silva, Ling Cheng, Thao T Doan, Karim R Masri   +9 more
doaj   +1 more source

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

Clinical and Translational Science, 2022
Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA) and recently approved by the European Medicines Agency for the treatment of psoriatic arthritis (PsA).
Elena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, Jaclyn K. Anderson, Mohamed‐Eslam F. Mohamed   +4 more
doaj   +1 more source

Efficacy of upadacitinib induction for pediatric inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Upadacitinib, a second‐generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD).
Evan Greenhall, Nina Gautam, Paula Prieto‐Jimenez, Elizabeth Hilow, Ashish Patel, Brad Pasternak   +5 more
wiley   +1 more source

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Global & Regional Health Technology Assessment, 2021
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy.
Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi   +3 more
doaj   +1 more source

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

JPGN Reports, EarlyView.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source

Upadacitinib in Active Non‐radiographic Axial Spondyloarthritis: 1‐Year Data From a Double‐Blind, Randomized, Placebo‐Controlled, Phase 3 Trial

ACR Open Rheumatology
Objective Upadacitinib improved the signs and symptoms of non‐radiographic axial spondyloarthritis (nr‐axSpA) versus placebo over 14 weeks in the primary analysis of the SELECT‐AXIS 2 nr‐axSpA study.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van derHeijde, Tae‐Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Yihan Li, Kristin D'Silva, Peter Wung, In‐Ho Song   +11 more
doaj   +1 more source